Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

General Rheumatology

Pfizer-BioNTech COVID-19 Vaccine Elicits Response Against Key Mutation

By

Diana Ernst, RPh

January 25, 2021

Antibodies elicited from the Pfizer-BioNTech COVID-19 vaccine can effectively neutralize SARS-CoV-2 with the mutation associated with rapid transmission.

Practice Management

FDA Urges HCPs to Follow Authorized Dosing Schedules for COVID-19 Vaccines

By

Diana Ernst, RPh

January 13, 2021

Additional research from the vaccine manufacturers would be needed to support any changes to the dosing schedule.

General Rheumatology

Moderna Increases Production Estimates of COVID-19 Vaccine for 2021

By

Diana Ernst, RPh

January 11, 2021

Moderna is increasing its baseline production estimates for its COVID-19 vaccine from 500 to 600 million doses for 2021.

General Rheumatology

Moderna’s COVID-19 Vaccine Gets EUA; Shipping Begins

By

Diana Ernst, RPh

December 22, 2020

The FDA has granted an EUA to Moderna’s COVID-19 vaccine, mRNA-1237, for active immunization.

General Rheumatology

Antibody Cocktail for COVID-19 Gets Emergency Use Authorization

By

Diana Ernst, RPh

November 30, 2020

The investigational treatment from Regeneron consists of 2 potent, virus-neutralizing antibodies.

Pediatric Rheumatology

Methotrexate Injection Now Available for Rheumatoid Arthritis, Juvenile Idiopathic Arthritis

By

Diana Ernst, RPh

November 20, 2020

RediTrex is approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriasis.

General Rheumatology

Interim Data Show COVID-19 Vaccine Candidate mRNA-1273 Nearly 95% Effective

By

Diana Ernst, RPh

November 17, 2020

A phase 3 trial evaluating the vaccine candidate mRNA-1273 against COVID-19 met its primary efficacy end point in the first interim analysis.

Practice Management

COVID-19 Vaccines: AstraZeneca Resumes Trial; Pfizer, BioNTech Look to Expand Study

By

Diana Ernst, RPh

September 21, 2020

AstraZeneca has resumed a phase 3 clinical trial investigating AZD1222, its COVID-19 vaccine candidate.

General Rheumatology

Emergency Use Authorization Issued for COVID-19 Convalescent Plasma

By

Diana Ernst, RPh

August 26, 2020

The FDA has issued an Emergency Use Authorization (EUA) for the use of COVID-19 convalescent plasma.

Rheumatoid Arthritis

FDA Rejects Filgotinib NDA for Rheumatoid Arthritis

By

Diana Ernst, RPh

August 25, 2020

The FDA has issued a CRL to Gilead Sciences related to the NDA for filgotinib in the treatment of moderately to severely active rheumatoid arthritis.

Next post in Rheumatoid Arthritis

elderly woman with pain

An Overview of Psychiatric Comorbidities in Rheumatoid Arthritis